# Do GLP-1 Drugs Help Bipolar Disorder? One Drug Moved, Two Did Not | This GLP Do GLP-1 drugs help bipolar disorder? A within-individual cohort of 14,694 people found 21% lower psychiatric hospitalization on semaglutide and nothing on two sibling drugs. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/do-glp1-drugs-help-bipolar-disorder Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Do GLP-1 Drugs Help Bipolar Disorder? One Drug Moved, Two Did Not Comparing people against their own untreated periods, psychiatric admissions fell 21% on semaglutide. Liraglutide and dulaglutide showed nothing. [This GLP Editorial Team](https://thisglp.com/about)September 20269 min read Psychiatric hospitalization, same person on vs off · semaglutide · 0.79 · liraglutide · no significant association · dulaglutide · no significant association · Sick leave from work: no association for any of them. · 14,694 people, 5,200 of them GLP-1 users. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). One drug in the class showed something, and the design is better than most. A nationwide cohort of 14,694 people with bipolar disorder and diabetes or obesity compared each person against their own periods on and off these drugs [\[1\]](https://thisglp.com/research/do-glp1-drugs-help-bipolar-disorder#ref-1). Semaglutide came with a 21% lower risk of psychiatric hospitalization, adjusted HR 0.79, 95% CI 0.69 to 0.91. Bipolar relapse was 17% lower at 0.83, 95% CI 0.69 to 0.99, while liraglutide and dulaglutide showed no association at all. Sick leave for psychiatric reasons, the outcome closest to daily life, did not move for any of them. No randomized trial has tested one of these drugs as a psychiatric treatment, and the authors ask for exactly that. ## Key takeaways - A nationwide cohort of 14,694 people with bipolar disorder and diabetes or obesity compared each person against their own periods on and off these drugs. - Semaglutide was associated with 21% lower risk of psychiatric hospitalization (adjusted HR 0.79, 95% CI 0.69-0.91) and 17% lower risk of bipolar relapse (aHR 0.83, 95% CI 0.69-0.99). - Liraglutide and dulaglutide showed no such association, so the authors conclude this is not a class effect. - Sick leave for psychiatric reasons showed no association with any of the drugs studied. People with bipolar disorder carry a heavy burden of obesity and diabetes, much of it produced by the medications that control the illness. A nationwide cohort spanning 2009 to 2024 asked whether treating the metabolic problem changes the psychiatric course[\[1\]](https://thisglp.com/research/do-glp1-drugs-help-bipolar-disorder#ref-1). The broader mortality picture in serious mental illness is in [a four-year mortality gap](https://thisglp.com/research/a-mortality-gap-in-serious-mental-illness). The design is the reason to take it seriously. Rather than comparing treated people against untreated people, it compares each person against themselves across periods when they were and were not taking one of these drugs. Everything stable about someone — how severe their illness is, their genetics, their circumstances — is identical in both periods and cancels out. In a condition where severity drives both what gets prescribed and who gets admitted, that removes the dominant objection — the same instrument used to good effect in [the alcohol discontinuation study](https://thisglp.com/research/what-happens-when-you-stop-drinking-on-it). Semaglutide was associated with a 21% lower risk of psychiatric hospitalization (adjusted HR 0.79, 95% CI 0.69–0.91) and a 17% lower risk of bipolar relapse (aHR 0.83, 95% CI 0.69–0.99). Liraglutide and dulaglutide showed no such association. One drug moving and two not is not a clean finding The authors read this as evidence against a class effect, and that is one reading. The other is that semaglutide users differ from liraglutide and dulaglutide users — they started more recently, are more often taking it for weight, and were selected by a prescriber making a different decision. A within-individual design removes differences between people; it does not remove differences between the periods in which each drug was fashionable. One outcome did not move at all, and it is the one closest to daily life. Sick leave for psychiatric reasons showed no association with any of the drugs studied. Hospitalization is a severe endpoint that also depends on admission thresholds and bed availability; sick leave tracks whether someone can work. A benefit that appears in one and not the other is narrower than the headline suggests. ## The two neighboring psychiatric results Two other findings sit next to this one and neither is about bipolar disorder. A target trial emulation matched 764,115 pairs starting a GLP-1 drug or an SGLT2 inhibitor, including 195,184 pairs with serious mental illness, and four-year mortality in that cohort was 4.91% against 6.45% [\[2\]](https://thisglp.com/research/do-glp1-drugs-help-bipolar-disorder#ref-2). That is a hazard ratio of 0.76 and an absolute difference of 1.54 percentage points, measured against another effective drug rather than against placebo. Separately, a 16-week double-blind trial randomized 72 adults with major depressive disorder to oral semaglutide 14 mg or placebo and found more willingness to exert effort as reward value rose, at P = .02 [\[3\]](https://thisglp.com/research/do-glp1-drugs-help-bipolar-disorder#ref-3). Its outcome was a laboratory task rather than a depression rating scale, which is set out in [the effort and reward trial](https://thisglp.com/research/motivation-in-depression-a-secondary-finding). The authors ask for a randomized trial, which is the right conclusion and an achievable one here — unlike many populations this site covers, people with bipolar disorder and obesity are numerous and already in regular contact with services. Until then this sits alongside the other psychiatric findings on this site, [the effort and reward trial](https://thisglp.com/research/motivation-in-depression-a-secondary-finding) and [the clozapine cohort](https://thisglp.com/research/do-glp1-drugs-help-antipsychotic-weight-gain), as a signal worth testing rather than a reason to prescribe. ## Frequently asked Do GLP-1 drugs help bipolar disorder? One nationwide cohort found semaglutide associated with 21% fewer psychiatric hospitalizations and 17% fewer relapses when people were taking it, compared with their own periods off it. Liraglutide and dulaglutide showed nothing, and no randomized trial has tested any of them. Does semaglutide help bipolar disorder? It was associated with fewer psychiatric hospitalizations and fewer relapses when people were taking it, compared with their own periods off it. The authors call for a randomized trial before treating that as an effect. Why did the other drugs show nothing? The authors read that as evidence against a class effect. An alternative is that people prescribed semaglutide differ from those prescribed liraglutide or dulaglutide, since the drugs became common at different times and for different reasons. Did anything else improve? No. Sick leave for psychiatric reasons showed no association with any of the drugs studied, which is the outcome closest to everyday functioning. ## Sources 1. \[1\] Taipale H, Taylor M, Lähteenvuo M, Mittendorfer-Rutz E, Tanskanen A (2026). Use of Glucagon-Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009-2024 Acta Psychiatrica Scandinavica. [PMID 42324672](https://pubmed.ncbi.nlm.nih.gov/42324672/) 2. \[2\] McIntyre RS, Zhang-James Y, Kwan ATH (2026). Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness JAMA Psychiatry. [PMID 42647034](https://pubmed.ncbi.nlm.nih.gov/42647034/) 3. \[3\] Gill H, Badulescu S, Shah H, Brudner RM, et al. (2026). Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial JAMA Psychiatry. [PMID 42054055](https://pubmed.ncbi.nlm.nih.gov/42054055/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)